Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

TDOC vs DBVT vs ALKS vs AMWL

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.26B
5Y Perf.-96.8%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+15.5%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+113.6%
AMWL
American Well Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$129M
5Y Perf.-98.7%

TDOC vs DBVT vs ALKS vs AMWL — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TDOC logoTDOC
DBVT logoDBVT
ALKS logoALKS
AMWL logoAMWL
IndustryMedical - Healthcare Information ServicesBiotechnologyBiotechnologyMedical - Healthcare Information Services
Market Cap$1.26B$1712.35T$5.90B$129M
Revenue (TTM)$2.51B$0.00$1.56B$182M
Net Income (TTM)$-171M$-168M$153M$-88M
Gross Margin65.6%65.4%38.7%
Operating Margin-7.6%12.3%-50.6%
Forward P/E24.8x
Total Debt$1.04B$22M$70M$5M
Cash & Equiv.$781M$194M$1.12B$182M

TDOC vs DBVT vs ALKS vs AMWLLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TDOC
DBVT
ALKS
AMWL
StockSep 20May 26Return
Teladoc Health, Inc. (TDOC)1003.2-96.8%
DBV Technologies S.… (DBVT)100115.5+15.5%
Alkermes plc (ALKS)100213.6+113.6%
American Well Corpo… (AMWL)1001.3-98.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: TDOC vs DBVT vs ALKS vs AMWL

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Teladoc Health, Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. DBVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
TDOC
Teladoc Health, Inc.
The Growth Play

TDOC is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth -1.5%, EPS growth 80.6%, 3Y rev CAGR 1.7%
  • -1.5% revenue growth vs DBVT's -100.0%
  • Better valuation composite
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
  • +110.4% vs TDOC's +1.5%
Best for: income & stability
ALKS
Alkermes plc
The Long-Run Compounder

ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • -11.0% 10Y total return vs TDOC's -41.1%
  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
  • 9.8% margin vs AMWL's -48.2%
Best for: long-term compounding and sleep-well-at-night
AMWL
American Well Corporation
The Secondary Option

AMWL lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthTDOC logoTDOC-1.5% revenue growth vs DBVT's -100.0%
ValueTDOC logoTDOCBetter valuation composite
Quality / MarginsALKS logoALKS9.8% margin vs AMWL's -48.2%
Stability / SafetyALKS logoALKSBeta 1.06 vs TDOC's 1.91, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs TDOC's +1.5%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

TDOC vs DBVT vs ALKS vs AMWL — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
AMWLAmerican Well Corporation
FY 2025
Platform Subscription
53.1%$132M
Visits
37.8%$94M
Others
9.1%$23M

TDOC vs DBVT vs ALKS vs AMWL — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGAMWL

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

TDOC and DBVT operate at a comparable scale, with $2.5B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTDOC logoTDOCTeladoc Health, I…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAMWL logoAMWLAmerican Well Cor…
RevenueTrailing 12 months$2.5B$0$1.6B$182M
EBITDAEarnings before interest/tax$42M-$112M$212M-$59M
Net IncomeAfter-tax profit-$171M-$168M$153M-$88M
Free Cash FlowCash after capex$251M-$151M$392M-$42M
Gross MarginGross profit ÷ Revenue+65.6%+65.4%+38.7%
Operating MarginEBIT ÷ Revenue-7.6%+12.3%-50.6%
Net MarginNet income ÷ Revenue-6.8%+9.8%-48.2%
FCF MarginFCF ÷ Revenue+10.0%+25.1%-22.9%
Rev. Growth (YoY)Latest quarter vs prior year-2.5%+28.2%-100.0%
EPS Growth (YoY)Latest quarter vs prior year+32.1%+91.5%-4.1%+44.5%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

TDOC leads this category, winning 4 of 5 comparable metrics.

On an enterprise value basis, TDOC's 15.1x EV/EBITDA is more attractive than ALKS's 17.3x.

MetricTDOC logoTDOCTeladoc Health, I…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAMWL logoAMWLAmerican Well Cor…
Market CapShares × price$1.3B$1712.35T$5.9B$129M
Enterprise ValueMkt cap + debt − cash$1.5B$1712.35T$4.9B-$48M
Trailing P/EPrice ÷ TTM EPS-6.11x-0.76x24.76x-1.30x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple15.13x17.25x
Price / SalesMarket cap ÷ Revenue0.50x4.00x0.52x
Price / BookPrice ÷ Book value/share0.89x0.66x3.28x0.50x
Price / FCFMarket cap ÷ FCF4.40x12.28x
TDOC leads this category, winning 4 of 5 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 7 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TDOC's 0.75x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.

MetricTDOC logoTDOCTeladoc Health, I…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAMWL logoAMWLAmerican Well Cor…
ROE (TTM)Return on equity-12.4%-130.2%+8.8%-33.5%
ROA (TTM)Return on assets-5.9%-89.0%+5.4%-25.1%
ROICReturn on invested capital-11.5%+18.9%-95.1%
ROCEReturn on capital employed-10.0%-145.7%+14.2%-36.6%
Piotroski ScoreFundamental quality 0–96476
Debt / EquityFinancial leverage0.75x0.13x0.04x0.02x
Net DebtTotal debt minus cash$259M-$172M-$1.0B-$178M
Cash & Equiv.Liquid assets$781M$194M$1.1B$182M
Total DebtShort + long-term debt$1.0B$22M$70M$5M
Interest CoverageEBIT ÷ Interest expense-8.76x-189.82x32.30x-239.18x
ALKS leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DBVT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, DBVT leads with a +110.4% total return vs TDOC's +1.5%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs AMWL's -42.2% — a key indicator of consistent wealth creation.

MetricTDOC logoTDOCTeladoc Health, I…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAMWL logoAMWLAmerican Well Cor…
YTD ReturnYear-to-date-1.3%+4.9%+25.3%+59.8%
1-Year ReturnPast 12 months+1.5%+110.4%+16.5%+14.3%
3-Year ReturnCumulative with dividends-73.3%+19.7%+14.5%-80.7%
5-Year ReturnCumulative with dividends-95.4%-69.1%+60.9%-97.2%
10-Year ReturnCumulative with dividends-41.1%-87.0%-11.0%-98.3%
CAGR (3Y)Annualised 3-year return-35.6%+6.2%+4.6%-42.2%
DBVT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than TDOC's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs TDOC's 71.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTDOC logoTDOCTeladoc Health, I…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAMWL logoAMWLAmerican Well Cor…
Beta (5Y)Sensitivity to S&P 5001.91x1.26x1.06x1.47x
52-Week HighHighest price in past year$9.77$26.18$36.60$9.15
52-Week LowLowest price in past year$4.40$7.53$25.17$3.71
% of 52W HighCurrent price vs 52-week peak+71.2%+76.3%+96.7%+84.7%
RSI (14)Momentum oscillator 0–10074.148.160.267.1
Avg Volume (50D)Average daily shares traded5.5M252K2.3M59K
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: TDOC as "Hold", DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 8.9% for TDOC (target: $8).

MetricTDOC logoTDOCTeladoc Health, I…DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAMWL logoAMWLAmerican Well Cor…
Analyst RatingConsensus buy/hold/sellHoldBuyBuy
Price TargetConsensus 12-month target$7.58$46.33$44.00
# AnalystsCovering analysts421528
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%+0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TDOC leads in 1 (Valuation Metrics).

Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...

TDOC vs DBVT vs ALKS vs AMWL: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is TDOC or DBVT or ALKS or AMWL a better buy right now?

For growth investors, Teladoc Health, Inc.

(TDOC) is the stronger pick with -1. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TDOC or DBVT or ALKS or AMWL?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TDOC or DBVT or ALKS or AMWL?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus Teladoc Health, Inc. 's 1. 91β — meaning TDOC is approximately 80% more volatile than ALKS relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — TDOC or DBVT or ALKS or AMWL?

By revenue growth (latest reported year), Teladoc Health, Inc.

(TDOC) is pulling ahead at -1. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — TDOC or DBVT or ALKS or AMWL?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -38. 4% for American Well Corporation — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — TDOC or DBVT or ALKS or AMWL?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is TDOC or DBVT or ALKS or AMWL better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between TDOC and DBVT and ALKS and AMWL?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TDOC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

AMWL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 23%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.